ArticleNature medicine2006
Human tissue-engineered blood vessels for adult arterial revascularization.
Article in Nature medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 289 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
289 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Concise Review: Patency of Small-Diameter Tissue-Engineered Vascular Grafts: A Meta-Analysis of Preclinical Trials.Stem cells translational medicine · 2019Pooled it
- A novel tissue-engineered stent graft combining decellularized scaffold and bioresorbable stent: a pilot feasibility study in a porcine model.Organogenesis · 2026Article
- Induced Pluripotent Stem Cell-Derived Small-Diameter Vascular Grafts: Scaffold Design, Immune Engineering, and Clinical Translation.Journal of cellular physiology · 2026Review
- Phosphatidylserine-everted erythrocyte membrane vesicles enhance efferocytosis and remodeling of vascular grafts.Nature communications · 2026Article
- Comparative analysis of different macromolecular crowding agents in human tenocyte cultures.Biomaterials and biosystems · 2026Article
- Degradable scaffold-mediated synergistic matrix formation by endogenous cells: an in vivo manufacturing strategy for off-the-shelf vascular grafts to address clinical shortages.Journal of nanobiotechnology · 2026Article
- Programmable Compliance in Small-Diameter Vascular Grafts by Design of Melt-Electrowritten Scaffold Architectures for In Situ Tissue Engineering.Advanced healthcare materials · 2026Article
- Barriers to clinical translation of small-diameter tissue-engineered vascular grafts in peripheral reconstruction.JVS-vascular science · 2026Review
- Construction of a Bioactive ECM Interface Enables Concurrent Suppression of Foreign Body Reaction, Inflammation, and Promotion of Urethral Regeneration.Biomaterials research · 2026Article
- Acellular Tissue Engineered Vessels as Coronary Artery Bypass Grafts.JACC. Basic to translational science · 2025Article
- Artificial blood vessels-clinical development of TEVG.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Review
- Future Frontiers in Bioinspired Implanted Biomaterials.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Bioengineered cardiovascular bypass grafts via in vivo self-assembly of scaffold-guided tubular tissue in rats.Journal of nanobiotechnology · 2025Article
- Autologous and synthetic vascular grafts trigger different host responses in the anastomotic regions and in the perivascular adipose tissue during the early healing phase.Materials today. Bio · 2025Article
- Endothelial Cells Increase Mesenchymal Stem Cell Differentiation in Scaffold-Free 3D Vascular Tissue.Tissue engineering. Part A · 2025Article
- Development and deployment of a functional 3D-bioprinted blood vessel.Scientific reports · 2025Article
- Immune-mediated regeneration of cell-free vascular grafts in an ovine model.NPJ Regenerative medicine · 2025Article
- Macromolecular Crowding for Reparative Medicine and Drug Discovery Applications.Sub-cellular biochemistry · 2025Review
- Case Report: Lessons learned from large animal implantation of an all-natural tissue engineered vascular graft.Frontiers in transplantation · 2025Article
- Construction of vascular grafts based on tissue-engineered scaffolds.Materials today. Bio · 2024Review
229 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
There is a crucial need for alternatives to native vein or artery for vascular surgery. The clinical efficacy of synthetic, allogeneic or xenogeneic vessels has been limited by thrombosis, rejection, chronic inflammation and poor mechanical properties. Using adult human fibroblasts extracted from skin biopsies harvested from individuals with advanced cardiovascular disease, we constructed tissue-engineered blood vessels (TEBVs) that serve as arterial bypass grafts in long-term animal models. These TEBVs have mechanical properties similar to human blood vessels, without relying upon synthetic or exogenous scaffolding. The TEBVs are antithrombogenic and mechanically stable for 8 months in vivo. Histological analysis showed complete tissue integration and formation of vasa vasorum. The endothelium was confluent and positive for von Willebrand factor. A smooth muscle-specific alpha-actin-positive cell population developed within the TEBV, suggesting regeneration of a vascular media. Electron microscopy showed an endothelial basement membrane, elastogenesis and a complex collagen network. These results indicate that a completely biological and clinically relevant TEBV can be assembled exclusively from an individual's own cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.